Pharmaceuticals

Budesonide Inhaler Market Anticipated to Grow Steadily, Approaching $10.25 Billion by 2030

March 29, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Market Value Is Expected For The Budesonide Inhaler Market At The End Of The 2026–2030 Forecast Period?

The budesonide inhaler market size has seen significant expansion in recent years. Its valuation is set to increase from $6.88 billion in 2025 to $7.45 billion in 2026, advancing at a compound annual growth rate (CAGR) of 8.3%. The growth observed historically can be attributed to factors such as asthma prevalence growth, increased COPD diagnosis rates, corticosteroid inhaler adoption, the expansion of hospital respiratory care, and smoking-related respiratory disorders.

The budesonide inhaler market is anticipated to observe robust expansion over the next few years. It is projected to climb to $10.25 billion by 2030, achieving a compound annual growth rate (CAGR) of 8.3%. This growth during the forecast period is largely attributable to the burden of chronic respiratory diseases, advancements in smart inhaler technology, the expansion of outpatient respiratory care, proactive asthma management strategies, and increasing demand from emerging markets. Prominent trends throughout the forecast period include a rising necessity for long-term respiratory control, increased adoption of combination inhalers, growth in homecare respiratory management, wider usage among pediatric and geriatric populations, and a strong focus on enhancing inhaler delivery efficiency.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24181&type=smp

What Major Growth Drivers Are Shaping The Outlook Of The Budesonide Inhaler Market?

The expanding prevalence of respiratory ailments is set to boost the budesonide inhaler market in the coming years. Respiratory disorders are medical conditions that affect the lungs and airways, making breathing difficult and often causing symptoms such as coughing, wheezing, and shortness of breath. These encompass conditions like asthma, chronic obstructive pulmonary disease (COPD), pneumonia, bronchitis, and various lung infections. The increase in respiratory disorders is primarily attributed to heightened air pollution, which elevates exposure to detrimental pollutants that irritate the airways and degrade lung function. Budesonide inhalers address respiratory disorders by directly delivering anti-inflammatory medication to the lungs, providing effective long-term control. Their compact design facilitates ease of use and portability, leading to a reduction in flare-ups and an improvement in respiratory health. For instance, in June 2025, Public Health Wales, a UK-based National Health Service organization in Wales, predicted that the number of patients on asthma and chronic obstructive pulmonary disease registers in Wales is projected to increase over the next 10 years. Additionally, asthma cases are expected to rise to over 256,000 registered cases from 237,400 cases in 2023-24, and chronic obstructive pulmonary disease cases are projected to increase to over 84,000 from 75,600 cases in 2023-24. Thus, the escalating incidence of respiratory disorders is a key driver for the growth of the budesonide inhaler market.

What Segment Types Make Up The Budesonide Inhaler Market?

The budesonide inhaler market covered in this report is segmented –

1) By Product Type: Metered-Dose Inhalers (MDIs), Dry Powder Inhalers (DPIs), Nebulizers, Combination Inhalers

2) By Dosage Form: Aerosols, Dry Powder, Suspension, Spray

3) By Indication: Asthma, Chronic Obstructive Pulmonary Disease, Allergic Rhinitis

4) By End User: Hospitals, Outpatient Clinics, Homecare Settings, Pharmacies

Subsegments:

1) By Metered-Dose Inhalers: Pressurized Metered-Dose Inhalers, Breath-Actuated Metered-Dose Inhalers, Spacer-Compatible Metered-Dose Inhalers, Hydrofluoroalkane Propellant-Based Metered-Dose Inhalers

2) By Dry Powder Inhalers: Single-Dose Dry Powder Inhalers, Multi-Dose Dry Powder Inhalers, Capsule-Based Dry Powder Inhalers, Reservoir-Based Dry Powder Inhalers

3) By Nebulizers: Jet Nebulizers, Ultrasonic Nebulizers, Mesh Nebulizers, Homecare Nebulizers, Hospital-Use Nebulizers

4) By Combination Inhalers: Budesonide And Formoterol Inhalers, Budesonide And Salmeterol Inhalers, Budesonide, Glycopyrrolate, And Formoterol Inhalers, Budesonide And Vilanterol Inhalers

Which Market Trends Are Creating New Opportunities In The Budesonide Inhaler Market?

Key players in the budesonide inhaler market are increasingly concentrating on the development of novel offerings, particularly generic options, to improve affordability and broaden access to treatments for various respiratory conditions. Generic inhaled medications are defined as non-proprietary versions of inhaled drugs that provide the same active components, dosage, and therapeutic outcomes as their branded counterparts, typically at a reduced cost. A notable example occurred in July 2023, when Viatris Inc., a US-based pharmaceutical company, in partnership with Kindeva Drug Delivery L.P., a US-based pharmaceutical manufacturing company, unveiled Breyna (budesonide and formoterol fumarate dihydrate) inhalation aerosol. This product marked the initial Food and Drug Administration (FDA), a US-based federal agency-approved generic version of Symbicort. This combined drug-device solution is formulated to address both asthma and chronic obstructive pulmonary disease (COPD), operating by leveraging budesonide to lessen inflammation in the airways, while formoterol works to relax the muscles surrounding the airways, thereby providing patients with a more economical option.

Who Are The Key Players Driving Competition In The Budesonide Inhaler Market?

Major companies operating in the budesonide inhaler market are AstraZeneca plc, GSK plc, Takeda Pharmaceutical Company Limited, Viatris Inc., Teva Pharmaceutical Industries Ltd., Boehringer Ingelheim International GmbH, Sandoz International GmbH, Bausch Health Companies Inc., Sun Pharmaceutical Industries Ltd., Synmosa Biopharma Corporation, Chiesi Farmaceutici S.p.A., Aurobindo Pharma Limited, Cipla Limited, Hikma Pharmaceuticals PLC, Lupin Limited, Orion Corporation, Nephron Pharmaceuticals Corporation, Curia Global Inc., Kindeva Drug Delivery L.P., Minakem SAS, Axplora Group GmbH, Cosmo Pharmaceuticals N.V., Manus Aktteva Biopharma LLP, Tovec Pharma Pvt. Ltd., Nutra Respiro Healthcare Pvt. Ltd.

Read the full budesonide inhaler market report here:

https://www.thebusinessresearchcompany.com/report/budesonide-inhaler-global-market-report

Which Regions Are Projected To Dominate The Budesonide Inhaler Market In The Coming Years?

North America was the largest region in the budesonide inhaler market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the budesonide inhaler market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Budesonide Inhaler Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=24181&type=smp

Browse Through More Reports Similar to the Global Budesonide Inhaler Market 2026, By The Business Research Company

Albuterol Market Report 2026

https://www.thebusinessresearchcompany.com/report/albuterol-global-market-report

Smart Inhalers Market Report 2026

https://www.thebusinessresearchcompany.com/report/smart-inhalers-global-market-report

Respiratory Inhaler Devices Market Report 2026

https://www.thebusinessresearchcompany.com/report/respiratory-inhaler-devices-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795